{"id":"W4393054377","doi":"10.3389/fonc.2024.1346502","title":"Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure","year":2024,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Melanoma; Tolerability; Pharmacokinetics; Drug; Pembrolizumab; Adverse effect; Rash; Dosing; Immune system; Pharmacology; Immunotherapy; Oncology; Cancer research; Immunology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001939267,0.002143654,0.001595554,0.0004140557,0.0005417559,0.001051572,0.0008278866,0.001525785,0.004011472],"category_scores_gemma":[0.0007762627,0.0008613659,0.001023669,0.0003346922,0.0009548472,0.0009395329,0.0003760585,0.003665159,0.001084063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00139763,"about_ca_system_score_gemma":0.002565475,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001469338,"about_ca_topic_score_gemma":0.004835629,"domain_scores_codex":[0.9994844,0.000153148,0.00001620698,0.0001201726,0.00006489159,0.0001610822],"domain_scores_gemma":[0.9994717,0.00005054806,0.0001113819,0.00004626596,0.00006103253,0.0002590213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.311307,0.2476136,0.01266443,0.001595563,0.001804867,0.000700612,0.000718771,0.007766745,0.235103,0.001029204,0.02321406,0.1564822],"study_design_scores_gemma":[0.1732592,0.7702968,0.01520724,0.00006634447,0.0005362642,0.0005296388,0.0001245352,0.002286706,0.02640125,0.0007463903,0.01048869,0.00005694976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737791,0.003223979,0.002361211,0.0007089755,0.0002205156,0.010516,0.005574647,0.0003016386,0.003313906],"genre_scores_gemma":[0.9682242,0.002279966,0.004549597,0.001619233,0.000154909,0.008184722,0.005807361,0.0001004116,0.009079576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004011472,"threshold_uncertainty_score":0.01341975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05279081540121635,"score_gpt":0.4166276137492951,"score_spread":0.3638367983480788,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}